<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:127169915;
mso-list-template-ids:2124429552;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:772286996;
mso-list-template-ids:-37046662;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.sfari.org/grant/pilot-awards-request-for-applications/__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MDgtLOy0$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Simons Foundation Autism Research Initiative: Winter 2020 Pilot
Award</span></a></span><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this
mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is
$300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years.<br>
<b>Due September 13, 2019. </b></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: September 3.</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.apa.org/apf/funding/walsh?tab=1__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MW27zwG8$" target="_blank"><span style="font-family:Palatino;color:#0563C1">American Psychological Foundation: Bruce and Jane Walsh Grant in Memory of John Holland</span></a></span><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Bruce and Jane Walsh Grant in Memory of John Holland supports scientific, scholarly or applied research and/or educational activities investigating
<b>how personality, culture and environment influence work behavior and health (mental and physical)</b>. Preference will be given to early career psychologists (ten years or less postdoctoral), and pilot projects that, if successful, would be strong candidates
for support from major federal and foundation funding agencies, and "demonstration projects" that promise to generalize broadly to similar settings in other geographical areas and/or to other settings. $15,000 for 1-year projects.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 15, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: September 3.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.scleroderma.org/site/SPageServer/?pagename=prof_research_types*.XU2BXtNKjfY__;Iw!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3M25kr69s$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Scleroderma Foundation: New and Established
Investigator Grant Programs</span></a></span><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Scleroderma Foundation seeks applications from promising new and established investigators both inside and outside the field of scleroderma research who wish to propose
pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to the disease. This grant will support pilot research that is likely to lead to more substantial unlimited research project grants from federal
or non-federal sources. New Investigator: 3 year projects; $50,000 per year; 8% IDC. Established Investigator: 2-year projects; $75,000 per year; 8% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 16, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: September 3.</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black"> </span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.fpwr.org/request-for-applications__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MoS5XSEA$"><span style="font-family:Palatino;color:#0563C1">Foundation for Prader-Willi Research</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Foundation for Prader-Willi Research was established in 2003 by a small group of parents who saw the need to foster research that would help their children with Prader-Willi syndrome
lead more healthy and fulfilling lives. Today, FPWR addresses the many issues related to PWS, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders. To advance this mission, FBWR is inviting LOIs for its Grants
Program. Through the program grants of up to $100,000 (with the possibility of a second year of funding) will be awarded in support of research that advances the understanding and treatment of Prader-Willi syndrome. Funding priorities identified by the foundation
include understanding how loss of PWS-critical genes leads to the phenotype; neurobiology of hunger/feeding behavior in PWS; neurobiology of cognitive deficits, maladaptive behavior and mental illness in PWS; clinical care research: evaluation of existing
drugs and interventions to improve health and quality of life in PWS; therapeutics development for PWS-genetic therapies; novel pharmaceuticals; and drug repurposing for PWS.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due September 16, 2019.<span style="color:black">
</span><span style="color:red">Med-RA deadline to receive draft documents: September 3.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.rwjf.org/en/library/funding-opportunities/2019/equity-focused-policy-research-building-evidence-on-nutrition-supports-for-low-income-families.html?rid=0034400001rm2ZLAAY&et_cid=1802727__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MszLDmeY$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Robert
Wood Johnson Foundation: Building Evidence on Nutrition Supports for Low-Income Families with Young Children</span></a></span><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this funding opportunity is to support action-oriented research that advances health equity, builds the knowledge base, and informs policymaking to
<b>increase access to nutrition supports and reduce nutrition disparities</b>. (RWJF is supporting research on the two other policy areas addressed in the research agenda—access to income supports and ECE—through separate calls for proposals.) Evidence generated
through funded projects should inform practice and policy and guide practitioners and policymakers (federal, state, and local) in setting priorities and allocating resources.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The Foundation is particularly interested in research on several federal nutrition programs that serve low-income families with young children and have the potential to help
address nutritional disparities. They include the following:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">The Supplemental Nutrition Assistance Program (SNAP), which provides benefits to supplement household resources for purchasing food;<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), which provides benefits redeemable for specific foods, nutrition
education, and breastfeeding support; and<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo1"><span style="font-size:12.0pt;font-family:Palatino">The Child and Adult Care Food Program (CACFP), which provides subsidies for meals and snacks served by child-care centers and family day-care
homes.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Research on other federal, state, and local nutrition programs may also be relevant to this opportunity, to the extent that they benefit or target families with young children
from birth to age 8.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Brief proposals due September 24, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: September 11.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-345.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MNdaceqk$" target="_blank"><span style="font-family:Palatino;color:#0563C1">NIDA Program Project Grant Applications (P01 Clinical Trial Optional)</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement announces the availability of support for collaborative research by multidisciplinary teams that is of high priority to NIDA and leads to synergistic
outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall
program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical
to advance the mission and goals of NIDA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for September 2019 deadline: September 12.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.aan.com/siteassets/home-page/education-and-research/research/aan-research-program/2020-katzman-updated-5-22.pdf__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MxI4Yc3I$" target="_blank"><span style="font-family:Palatino;color:#0563C1">American
Academy of Neurology: Robert W. Katzman, MD, Clinical Research Training Scholarship in Alzheimer's and Dementia Research</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The American Academy of Neurology (AAN) strives to promote the highest quality patient-centered neurologic care and enhance member career satisfaction. To that end, and in collaboration
with the Alzheimer’s Association and the American Brain Foundation, AAN is inviting applications for the Robert W. Katzman, MD, Clinical Research Training Scholarship in Alzheimer's and Dementia Research. Through the award, a single award of $65,000 per year
for two years plus a $10,000 annual stipend will be awarded to a young investigator in support of clinical research on Alzheimer's or a related dementia. For the purpose of this scholarship, research is defined as "patient-oriented research conducted with
human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurologic disease." Priority areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development
of new technologies, diagnostic tests after clinical trials in phase 1, and health services and outcomes research. Disease-related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies,
diagnostic tests, or other tools to prevent or mitigate neurological diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To be eligible, applicants must be an AAN member and must have completed residency or a PhD no more than five years prior to the beginning of the award (July 1, 2020). If applicants have
completed both their residency and a PhD, eligibility is based on when residency was completed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 1, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: September 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://www.rwjf.org/en/library/funding-opportunities/2019/policies-for-action-increasing-diversity-in-policy-and-law-research.html?rid=0034400001rm2ZLAAY&et_cid=1795400__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3Mz-Hp730$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Robert
Wood Johnson Foundation: Advancing Equity, Diversity, and Inclusion in Policy and Law Research--for Early Career Investigators</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Policies for Action (P4A)</span></b><span style="font-size:12.0pt;font-family:Palatino">, a signature research program of the Robert Wood Johnson Foundation, is issuing a special call
for proposals (CFP) to advance health equity by actively seeking new and diverse perspectives from the policy research field. This opportunity is designed to support researchers from multiple disciplines to better understand and find solutions that will promote
health equity and foster action on policies and laws that ensure all people in America can attain and preserve good health and well-being. This opportunity will support
<b>early career researchers from underrepresented and historically disadvantaged backgrounds</b> to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Engage in career development activities and mentorship that will enhance their research capacity;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Develop a research project that examines existing policies or policy changes that can influence population health, well-being, and equity;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Produce and translate timely research results; and<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><span style="font-size:12.0pt;font-family:Palatino">Collaborate with other researchers to create a healthier, more equitable future for all people in America.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">P4A will provide support and training for up to six investigators. Two of these six will be researchers located in and conducting research within the state of New Jersey. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due October 2, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: September 19.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-339.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MJ0_K2FM$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R21</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-340.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MWaJ234c$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R01</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These FOAs encourage the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central
nervous system malignancies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; and June 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: September 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-350.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MaBAdCzg$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R21</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-348.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3M9Km1nFQ$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R01</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through these Funding Opportunity Announcements, the National Cancer Institute announces its interest in supporting meritorious research projects in three distinct domains related to cancer
communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel
cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control.
Applications should utilize one or more innovative communication research methodologies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">October 9, 2019; June 10, 2020; October 14, 2020; June 9, 2021; October 13, 2021; and June 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: September 26.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-016.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MMHdFTYY$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Circadian Patterns of Gene Expression Associated with Disease (R01
– Clinical Trial Optional)</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to identify abnormalities in circadian-ordered gene expression to improve our understanding of disease phenotypes, etiology, risk
stratification, resilience, and therapeutic management in diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 7, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: September 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 / R21 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-19-347.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3M5YfHnec$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R03</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-346.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MH14rOWE$" target="_blank"><span style="font-family:Palatino;color:#0563C1">R21</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity,
to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for October 2019 deadline: October 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-030.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MkYdCw4Q$" target="_blank"><span style="font-family:Palatino;color:#0563C1">Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated
Clinical Trials (UG3/UH3 – Clinical Trial Required)</span></a></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications
proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents
one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions
to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance
into clinical trials.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational
plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see
</span><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MK_Dxkxk$"><span style="font-family:Palatino;color:#0563C1">NOT-OD-15-015</span></a></span><span style="font-size:12.0pt;font-family:Palatino">). Applications
will be required to include plans for project management, participant recruitment and retention , performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational
New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples
of the source stem cell and clinical-grade stem cell-derived product for in-depth and independent characterization through the RM Innovation Catalyst (see description in Section I). Due to the complex nature of requirements in this FOA (e.g., 1:1 matching
funds, resource sharing), applicants are strongly encouraged to communicate with the appropriate NIH Scientific/Research Contact and review online
</span><span style="font-size:12.0pt"><a href="https://urldefense.com/v3/__http://www.nih.gov/rmi/frequently-asked-questions__;!5Xm4_O-4tfk!iaR4vo85GWlwe6_bR6KqjE-ufPsbi3C8pLkySIhKKviWKjS02mGs8yS8IL2rPueDj3f_VOJCZX3MJyDiWog$"><span style="font-family:Palatino;color:#0563C1">Frequently Asked Questions (FAQs)</span></a></span><span style="font-size:12.0pt;font-family:Palatino"> prior
to submitting an application. Staff will be able to advise applicants in determining if their research meets the requirements and objectives of this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 18, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: October 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="font-family:Palatino;color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"> <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>